We would love to hear your thoughts about our site and services, please take our survey here.
RNS SAID
Helium One is in advanced discussions with a leading global drilling company for the provision of a containerised rig solution.
So I'm confident it will come through
Been reading alot of commits on here and my take alot are derapping just to buy more shares in the company.
The problem is blue people like you believe what they see in the news, are people of Palestine dont have the right to defend they land. Check the history that land belongs to Palestine. So before you say anything read the history.
@FORDM your totally right why should we all suffer because of Ukraine . I didn't see any countries saying anything about Palestine when the when the Israeli forces were killing kids and women last year.
I was doing the same with odx and hoping there would get approval in America and eu, by the time approval came we were 10p, dont throw more money in sng your better investing in other companies. And dont listen to anyone on here make your own judgement
Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19
Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well tolerated in this population.
Richard Marsden, CEO of Synairgen, commented: "While we are disappointed by the overall outcome, SNG001 has been administered to hospitalised patients on top of standard of care which changed substantially between our Phase 2 and Phase 3 trials. This improvement in patient care may have compromised the potential of SNG001 to show a clinical benefit in respect of the endpoints for this study, which were not met. Despite this we have observed an encouraging trend in prevention of progression to severe disease and death, which we strongly believe merits further investigation in a platform trial. We are now analysing the full dataset to better understand all the findings."
"In the meantime, we eagerly await the Phase 2 data from the US NIH ACTIV-2 trial in home- based COVID-19 patients, and that trial's larger, follow-on Phase 3 study, as part of the development path for SNG001."
Efficacy
A total of 623 patients were randomised to receive SNG001 (n=309) or placebo (n=314) in addition to standard of care (SOC). The primary analysis was conducted in the intention-to-treat population (ITT; all randomised patients). Data for the per protocol population (PP) is also shown. The PP population excludes patients with major protocol violations that may have confounded the results.
Primary Endpoints
Regarding the primary endpoints (Table 1), patients who received SNG001 were no more likely to be discharged from hospital than patients who received placebo, and patients who received SNG001 were also no more likely to recover to 'no limitation of activities' than patients who received placebo, in both the ITT and PP populations. The evolution in standard of care over the course of the pandemic (for example, 87% of patients in this trial received systemic corticosteroids for COVID-19 at baseline whereas none did in the Phase 2 study of SNG001 in COVID-19 ([1]) ) may have compromised the potential of SNG001 to show a clinical benefit in respect of the primary endpoints for this study.
Table 1: Primary Endpoints
Lft has done alot of people over, people have lost thousands of pounds, people need to get real and stop about wishful thinking, LFT IS DEAD SIMPLE. I BOUGHT AVCT when approval was granted and 1 month after that we can RNS to say the test are ****. I feel we all have been done over by the company. People on here need to realise WE CAN'T TRUST THE COMPANY.